---
$id: https://graph.org.ai/products/commodity/51322804
$type: Product
source: UNSPSC
code: "51322804"
title: "Acipimox"
class: "51322800"
classTitle: "Antihyperlipidemic and hypocholesterolemic nicotinic acids"
family: "51320000"
familyTitle: "Antihyperlipidemic and hypocholesterolemic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Acipimox

**UNSPSC Code**: 51322804
**Class**: [Antihyperlipidemic and hypocholesterolemic nicotinic acids](Antihyperlipidemic and hypocholesterolemic nicotinic acids.mdx)
**Family**: [Antihyperlipidemic and hypocholesterolemic agents](../Antihyperlipidemic and hypocholesterolemic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an anti-lipidemic agent with the molecular formula C6H6N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier K9AY9IR2SD, chemically known as 2-pyrazinecarboxylic acid, 5-methyl-, 4-oxide but more generally known as acipimox, which bears U.S. NIH Compound Identifier 39880. European Medicines Agency schedules Acipimox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05237MIG. The term ACIPIMOX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules acipimox in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. ACIPIMOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

